Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined With TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer

NCT06793332 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06793332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined With TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
December 17, 2024
Completion date
January 31, 2027
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, triple-negative breast cancer (tnbc)